TD Waterhouse Canada’s Akebia Therapeutics AKBA Stock Holding History

TD Waterhouse Canada’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$461	Hold	327	–	–	﹤0.01%	2157
2025 Q4	$523	Hold	327	–	–	﹤0.01%	1909
2025 Q3	$876	Hold	327	–	–	﹤0.01%	1902
2025 Q2	$1.16K	Hold	327	–	–	﹤0.01%	1793
2025 Q1	$621	Sell	327 -98,291	-100%	-$201K	﹤0.01%	1781
2024 Q4	$187K	Buy	98,618 +8,000	+9%	+$13.9K	﹤0.01%	811
2024 Q3	$115K	Buy	90,618 +65	+0.1%	+$87	﹤0.01%	864
2024 Q2	$90.2K	Buy	90,553 +50,000	+123%	+$61.8K	﹤0.01%	908
2024 Q1	$79.9K	Hold	40,553	–	–	﹤0.01%	955
2023 Q4	$75.5K	Hold	40,553	–	–	﹤0.01%	865
2023 Q3	$57.9K	Hold	40,553	–	–	﹤0.01%	887
2023 Q2	$45.7K	Buy	40,553 +39,000	+2,511%	+$37.6K	﹤0.01%	950
2023 Q1	$1.16K	Hold	1,553	–	–	﹤0.01%	1581
2022 Q4	$1.26K	Hold	1,553	–	–	﹤0.01%	1540
2022 Q3	$633	Hold	1,553	–	–	﹤0.01%	1609
2022 Q2	$746	Hold	1,553	–	–	﹤0.01%	1640
2022 Q1	$1.26K	Buy	1,553 +262	+20%	+$561	﹤0.01%	1645
2021 Q4	$3.87K	Buy	+1,291	New	+$3.52K	﹤0.01%	1491

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

TD Waterhouse Canada's AKBA Position: Q1 2026 in Review

TD Waterhouse Canada held its Akebia Therapeutics (AKBA) position steady in Q1 2026 at 327 shares worth $461. The position accounts for ﹤0.01% of the portfolio, ranked #2157.

TD Waterhouse Canada first reported a position in AKBA in Q4 2021 and has held it in 18 quarters since. The position peaked at $187K in Q4 2024. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

TD Waterhouse Canada held 327 shares of Akebia Therapeutics worth $461 as of Q1 2026.
TD Waterhouse Canada left its Akebia Therapeutics share count unchanged in Q1 2026.
Akebia Therapeutics made up ﹤0.01% of TD Waterhouse Canada's portfolio in Q1 2026, its #2157 holding.
TD Waterhouse Canada first reported a position in Akebia Therapeutics in Q4 2021 and has held it in 18 quarters since.
TD Waterhouse Canada's Akebia Therapeutics position peaked at $187K in Q4 2024.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on TD Waterhouse Canada's 13F filing for Q1 2026, filed 12 May 2026.